The article discusses Joe Biden’s strong emphasis on cancer research during his time as vice president and president, contrasting it with Donald Trump’s approach. Biden’s “moonshot” initiative prioritized cancer research, while Trump’s administration is reportedly reducing funding for the National Cancer Institute and cutting cancer-related research grants. Under Trump’s leadership, hundreds of millions in cancer research funding has been canceled or delayed, with a proposed 37% budget cut for the National Cancer Institute, the lowest funding level in over 30 years.
The timing of these cuts is noted as particularly detrimental, as the U.S. is experiencing significant breakthroughs in cancer research. Jonathan Mahler highlights the long-term impacts of these funding reductions, which could deplete the nation’s scientific talent and innovation, ultimately affecting future cancer patients. Dr. Kamila Naxerova expresses concern that those diagnosed with cancer in the coming decades will bear the brunt of these budget cuts. The article underscores the potential consequences of a Republican victory in the 2024 election on cancer research funding, signaling significant repercussions for the field.
